Home Cart Sign in  
Chemical Structure| 905579-51-3 Chemical Structure| 905579-51-3

Structure of Pevonedistat
CAS No.: 905579-51-3

Chemical Structure| 905579-51-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Pevonedistat (MLN4924) showcases potent and selective inhibition of NEDD8-activating enzyme (NAE), with an IC50 of 4.7 nM.

Synonyms: MLN4924

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Pevonedistat

CAS No. :905579-51-3
Formula : C21H25N5O4S
M.W : 443.52
SMILES Code : O=S(OC[C@H]1[C@@H](O)C[C@H](N2C=CC3=C(N[C@H]4CCC5=C4C=CC=C5)N=CN=C32)C1)(N)=O
Synonyms :
MLN4924
MDL No. :MFCD17215201
InChI Key :MPUQHZXIXSTTDU-QXGSTGNESA-N
Pubchem ID :16720766

Safety of Pevonedistat

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Normal human cholangiocytes (NHCs) and polycystic human cholangiocytes (PHCs) 0.05 μM 24 and 48 h To evaluate the effect of Pevonedistat on cystic cholangiocytes, results showed that Pevonedistat significantly inhibited proliferation and induced apoptosis in cystic cholangiocytes. PMC8435261
RP-Lung SCLC 1.8 ± 0.21 μM 72 h To evaluate the inhibitory effect of Pevonedistat on SCLC cell proliferation, the results showed an IC50 of 1.8 ± 0.21 μM PMC7272287
RP-LvMet SCLC 0.18 ± 0.08 μM 72 h To evaluate the inhibitory effect of Pevonedistat on SCLC cell proliferation, the results showed an IC50 of 0.18 ± 0.08 μM PMC7272287
H69 SCLC 8.7 ± 1.1 μM 72 h To evaluate the inhibitory effect of Pevonedistat on SCLC cell proliferation, the results showed an IC50 of 8.7 ± 1.1 μM PMC7272287
Human cystic cholangiocytes 0.05 μM 24 and 48 h To evaluate the effect of Pevonedistat on the proliferation and apoptosis of cystic cholangiocytes, results showed that Pevonedistat significantly inhibited proliferation and induced apoptosis in cystic cholangiocytes. PMC8435261
FaDu 30-3000 nM 72 h To evaluate the effect of Pevonedistat on the viability of HNSCC cell lines, results showed that Pevonedistat reduced the viability of HNSCC cells in a dose-dependent manner. PMC9012827
FaDu 300 nM 24 h To evaluate the effect of Pevonedistat on DNA damage, results showed that Pevonedistat significantly increased 8-oxoguanine levels, indicating it induces DNA damage. PMC9012827
FaDu 100-1000 nM 24 h To evaluate the effect of Pevonedistat on colony formation in HNSCC cells, results showed that Pevonedistat significantly decreased the clonogenic potential of HNSCC cells. PMC9012827
Cal27 cells 50 nM 24 or 48 h Inhibited cullin neddylation, increased levels of the CRL4CDT2 substrate p21, and resulted in the accumulation of DNA damage. PMC5805645
FaDu cells 50 nM 24 or 48 h Inhibited cullin neddylation, increased levels of the CRL4CDT2 substrate p21, and resulted in the accumulation of DNA damage. PMC5805645
Cal27 50 nM 24 or 48 h Inhibition of cullin neddylation, increased levels of CRL4CDT2 substrate p21 PMC5805645
FaDu 50 nM 24 or 48 h Inhibition of cullin neddylation, increased levels of CRL4CDT2 substrate p21 PMC5805645
RMC2C 0.13 μM 48 h To evaluate the inhibitory effect of Pevonedistat on RMC2C cells, the results showed that Pevonedistat significantly inhibited cell growth with an IC50 concentration of 0.13 μM. PMC10210052
RMC219 0.26 μM 48 h To evaluate the inhibitory effect of Pevonedistat on RMC219 cells, the results showed that Pevonedistat significantly inhibited cell growth with an IC50 concentration of 0.26 μM. PMC10210052

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
mice subcutaneous xenograft models subcutaneously 50 or 90 mg/kg Daily treatment continued until the end of the experiment To evaluate the inhibitory effect of Pevonedistat on SCLC tumors, the results showed that Pevonedistat significantly inhibited tumor growth PMC7272287
Mice HNSCC xenograft model Subcutaneous injection 60 mg/kg 5 times per week for 3 weeks To evaluate the effect of Pevonedistat in combination with cisplatin on HNSCC tumors, results showed that the combination significantly reduced tumor burden and promoted long-term survival. PMC9012827
Nude mice HNSCC xenograft model Intraperitoneal injection 20 mg/kg 5 days on/5 days off for 2 cycles Pevonedistat significantly suppressed Cal27 xenografts and further enhanced tumor growth suppression when combined with ionizing radiation (IR). PMC5805645
Mice HNSCC xenograft model Intraperitoneal injection 20 mg/kg 5 days on/5 days off for 2 cycles To test the effect of Pevonedistat on HNSCC tumor growth, results showed that Pevonedistat significantly suppressed Cal27 xenografts PMC5805645
Mice RMC2X and RMC32X PDX models Intraperitoneal injection 30 mg/kg Pevonedistat daily for 5 days with 2 days off, 7 days per cycle; Carboplatin and Paclitaxel once per week, 7 days per cycle. To evaluate the anti-tumor effect of Pevonedistat in combination with Carboplatin and Paclitaxel on RMC2X and RMC32X PDX models, the results showed that the combination therapy significantly inhibited tumor growth. PMC10210052

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01011530 Metastatic Melanoma PHASE1 COMPLETED 2025-01-13 The Angeles Clinic and Researc... More >>h Institute, Santa Monica, California, 90404, United States Less <<
NCT00722488 Hematologic Malignancies|Multi... More >>ple Myeloma|Lymphoma|Hodgkin Lymphoma Less << PHASE1 COMPLETED 2025-09-13 Winship Cancer Institute, Atla... More >>nta, Georgia, 30322, United States|Roswell Park Cancer Institute, Buffalo, New York, 14263, United States Less <<
NCT00677170 Advanced Nonhematologic Malign... More >>ancies Less << PHASE1 COMPLETED 2025-12-12 Emory University Hospital, Atl... More >>anta, Georgia, 30322, United States|Cancer Therapy & Research Center at the UT Health Science Center, San Antonio, Texas, 78229, United States|Institute for Drug Development, San Antonio, Texas, 78229, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.25mL

0.45mL

0.23mL

11.27mL

2.25mL

1.13mL

22.55mL

4.51mL

2.25mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories